Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable ...

SK Capital Partners is considering a sale of Geon Performance Solutions that could value the chemical maker at about $2 billion, according to people with knowledge of the matter. The private ...

That’s what Carlyle and SK Capital are paying for the 15-year-old Massachusetts biotech in a deal that was announced on Friday. There is a catch. If the private equity firms can boost sales of ...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon ...

Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia ...

As part of the agreement, Carlyle Group (NASDAQ:CG) and SK Capital will also provide bluebird (NASDAQ:BLUE) with primary capital to expand the commercial reach of its gene therapies targeted at ...

(“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the ...

“The bluebird Board considered all reasonable alternatives during its review of strategic alternatives and concluded that the proposed transaction with Carlyle and SK Capital is the only viable ...

SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of ...